Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

Inflammatory Bowel Disease

Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis

J Crohns Colitis

Massironi S, Solitano V, Furfaro F, D'Amico F, Zilli A, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S

doi: 10.1093/ecco-jcc/jjaf157

Hepatology

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Clin Gastroenterol Hepatol

Vidal-Trécan T, Julla JB, El Khoury T, Venteclef N, Riveline JP, Paradis V, Valla D, Gautier JF, Castera L

doi: 10.1016/j.cgh.2025.02.018

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Inflammatory Bowel Disease

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis

Adv Ther

Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB

doi: 10.1007/s12325-025-03447-6

Further Publications

Comparative Efficacy and Safety of 0.8-L Versus 2-L Polyethylene Glycol-Ascorbic Acid Solutions in Colonoscopy Preparation: A Prospective, Multicenter, Randomized, Controlled Trial

J Gastroenterol Hepatol

Lee B, Keum B, Hong SN, Kim HG, Im JP, Na SY, Kwak MS, Nam K, Byeon JS

doi: 10.1111/jgh.70006

Hepatitis

Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis

Hepatology

Li J, Xu L, Rui F, Tran S, Tsai PC, Tan Y, Toyoda H, Zeng QL, Trinh H, Hsu YC, Watanabe T, Abe H, Motoyama H, Yoshimaru Y, Suzuki T, Arai T, Atsukawa M, Vutien P, Marciano S, Bai X, Ni W, Geng N, Tseng CH, Liu J, Mi Y, Liu J, Ye Y, Zhu L, Chen RY, Zhu C, Maeda M, Liu JK, Henry L, Yeh ML, Huang CF, Huang JF, Dai CY, Gadano A, Cheung R, Chuang WL, Enomoto M, Tanaka Y, Aishima S, Yu ML, Wu C, Shi J, Nguyen MH

doi: 10.1097/HEP.0000000000001442

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

HepatologyFurther Publications

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Lancet Gastroenterol Hepatol

Wong VW, Amin NB, Takahashi H, Darekar A, Tacke F, Kiszko J, Rodriguez H, Nakajima A, Alkhouri N, Charlton M, Anstee QM

doi: 10.1016/S2468-1253(25)00128-1

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Related content

Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis

Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis

Comparative Efficacy and Safety of 0.8-L Versus 2-L Polyethylene Glycol-Ascorbic Acid Solutions in Colonoscopy Preparation: A Prospective, Multicenter, Randomized, Controlled Trial

Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis